FDA Application Submitted for Darzalex Combo Therapy to Treat Certain Multiple Myeloma Patients
An application has been submitted seeking U.S. approval of Darzalex (daratumumab) in combination with standard pre-transplant therapy to treat newly diagnosed multiple myeloma patients who are eligible for a stem cell transplant. Janssen‘s supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) is for a…